Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
224 hedge funds and large institutions have $4.1B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2021 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 82 increasing their positions, 90 reducing their positions, and 46 closing their positions.
29% more call options, than puts
Call options by funds: $64.1M | Put options by funds: $49.5M
9% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 90
6% less funds holding
Funds holding: 238 → 224 (-14)
14% less capital invested
Capital invested by funds: $4.78B → $4.1B (-$680M)
17% less funds holding in top 10
Funds holding in top 10: 12 → 10 (-2)
26% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$58.1M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$49.3M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$45.1M |
| 4 |
GCM
Glenview Capital Management
New York
|
+$37.1M |
| 5 |
AC
Armistice Capital
New York
|
+$34.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
-$29.9M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19.7M |
| 3 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$19.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.1M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$18.2M |
BHVN Hedge Fund Activity: Q1 2021 in Review
224 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q1 2021, worth a combined $4.1B — down 14% from $4.78B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of BHVN and 34 opened new positions — a net loss of 12 holders — while 90 trimmed existing stakes and 82 added.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $58.1M. The largest seller was Kingdon Capital Management, cutting an estimated $29.9M.
- 224 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q1 2021, down from 238 in Q4 2020.
- Funds reported $4.1B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q1 2021, down 14% quarter-over-quarter.
- 34 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q1 2021 and 46 closed out, a net change of -12 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q1 2021 was Janus Henderson Group, an estimated $58.1M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q1 2021 was Kingdon Capital Management, an estimated $29.9M sold.
Based on aggregated 13F filings for Q1 2021.